GV, Alphabet Inc's venture capital arm, led a US$58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The company said it will only develop treatments that involve editing adult cells, so the effects of genetic manipulation cannot be passed on to future generations.
Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Brazil cosmetics company Natura to invest US$5m in new brands through venture capital funds[SAO PAULO] Brazil cosmetics company Natura intends to invest up to US$5 million in new brands in beauty and wellness segments in Europe and the United States through venture capital funds, executives said on Friday. Read more at The Business Times.
Fonte: BusinessTimes - 🏆 15. / 51 Leggi di più »
More funds to help companies train workers, raise wages
Fonte: TODAYonline - 🏆 1. / 99 Leggi di più »
More funding for companies that work with unions to prepare workers for transformation: DPM HengSINGAPORE - Technological advancements should help workers do their jobs better, not replace them, said Deputy Prime Minister Heng Swee Keat on Wednesday (May 1).. Read more at straitstimes.com.
Fonte: The Straits Times - 🏆 8. / 63 Leggi di più »